Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements of Operations and Comprehensive (Loss) Income
Net sales	$ 5,492,524	$ 4,485,230	$ 4,410,388
Cost of sales	(5,116,515)	(4,211,085)	(4,144,802)
Gross profit	376,009	274,145	265,586
Selling, general and administrative expenses	(335,650)	(255,580)	(213,705)
Goodwill impairments	(224,966)
Impairments of definite-lived intangible assets	(82,678)		(4,804)
(Loss) income from operations	(267,285)	18,565	47,077
Other (expense) income:
Interest expense	(41,650)	(10,716)	(6,573)
Equity loss and impairment of non-consolidated entities	(329)		(4,659)
Other	1,956	213	370
Total other expense	(40,023)	(10,503)	(10,862)
(Loss) income before income taxes	(307,308)	8,062	36,215
Income tax benefit (expense)	5,039	7,126	(11,195)
Net (loss) income	(302,269)	15,188	25,020
Less net loss attributable to noncontrolling interest		(322)	(3,253)
Net (loss) income attributable to Diplomat Pharmacy, Inc.	(302,269)	15,510	28,273
Other comprehensive loss, net of tax	(4,292)
Total comprehensive (loss) income	$ (306,561)	$ 15,510	$ 28,273
(Loss) income per common share:
Basic (in dollars per share)	$ (4.07)	$ 0.23	$ 0.43
Diluted (in dollars per share)	$ (4.07)	$ 0.23	$ 0.42
Weighted average common shares outstanding:
Basic (in shares)	74,244,520	68,130,322	65,970,396
Diluted (in shares)	74,244,520	68,780,053	68,047,723